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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The objective of this review is to assess the effects of long-term oral and inhaled antibiotic therapy targeted against chronic BCC lung
infections in people with CF. The primary objective is to assess the efficacy of treatments in terms of improvements in lung function
and reductions in exacerbation rate. Secondary objectives include quantifying adverse events, mortality and changes in quality of life
associated with treatment.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a common life-threatening inherited disease
affecting over 10,000 people in the UK, 35,000 in Europe and
30,000 in the USA (CFF 2016; CF Trust 2014; Farrell 2008).
There have been significant improvements in CF survival since the
1930s when 70% of those with CF died in infancy, to a current
median predicted survival of 43.5 years (CF Trust 2014). Early CF
deaths are now rare: over 95%of childrenwithCF enter adulthood
and those born in this century can expect to survive into at least
their sixth decade. Recent predictions are that the number of CF
adults will increase by 78% by 2025 (Burgel 2015).
In CF, the genetic autosomal-recessive defect in the CFTR protein
causes abnormal salt and water movements across mucus-produc-
ing cell surfaces. This results in thick mucus leading to a combi-
nation of infection and inflammation with subsequent local organ
damage, which is most apparent in the lungs and pancreas, but
affects many other organs. In the lungs the hallmarks of disease are
chronic airway inflammation and chronic infection with difficult
to treat pathogens, such as Pseudomonas aeruginosa, Staphylococcus
aureus and Burkholderia cepacia complex (BCC). Chronic airway
infection is associated with a progressive loss of lung function,
which is the primary cause of death in people with CF (Corey
1997).
BCC is comprised of a group of over 20 closely related species
with a cumulative annual prevalence in people with CF of 3%
to 5%; Burkholderia cenocepacia and Burkholderia multivorans
account for 85% to 97% of BCC infections (CFF 2016; CF
Trust 2017; Drevinek 2010;Mahenthiralingam 2002; Vandamme
2011). These two pathogens are associated with poor outcomes
including accelerated pulmonary decline, a necrotizing pneumo-
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nia known as ’cepacia syndrome’ and a higher mortality rate (Aris
2001; Mahenthiralingam 2002; Zlosnik 2015). B cenocepacia is
the more pathogenic of the two, with an increased likelihood of
chronic infection and reduced survival compared to B multivo-
rans (Jones 2004; Mahenthiralingam 2001). Acquisition is often
from environmental sources, but clonal transmission of epidemic
strains has been extensively reported, particularly forB cenocepacia,
and hence infection control and segregation measures are required
to prevent cross-infection (Ledson 1998; LiPuma 2010; Zlosnik
2015).
Resistance to aminoglycosides, to most beta-lactams as well as to
polymyxins is common within BCC and some species have the
ability to develop resistance to any agent resulting in pan-resistant
strains (CF Trust 2017;Drevinek 2010;Mahenthiralingam 2002).
Therefore, the clinical management of chronic BCC infection in
CF poses a challenge to clinicians.
Description of the intervention
Long-term antibiotics are one of themainstays of treatment in peo-
ple with CF with chronic infection. Administration is usually via
the inhaled or oral route and aims to reduce the bacterial burden
in sputum. Inhaled antibiotics allow rapid deposition of high con-
centrations of antibiotic direct to the site of action and hence rep-
resent an attractive strategy. In those with P aeruginosa infection,
colistimethate, tobramycin and aztreonam have all demonstrated
clinical benefit (Gibson 2003;McCoy 2008; Retsch-Bogart 2008;
Ryan 2011). The low systemic absorption associated with inhaled
antibiotics can help avoid some of the side-effects seen with intra-
venous antibiotics used in acute infection (Weber 1995).
Oral antibiotics are quick and convenient to take, but may not
be able to deliver as high a concentration to the lung as inhaled
formulations.Nevertheless, oralmacrolide therapy has been shown
tobe effective inCFwith a recentCochraneReviewdemonstrating
a reduction in pulmonary exacerbations and improved respiratory
function after six months treatment of azithromycin (Southern
2012).
How the intervention might work
Long-term antibiotic therapy targeted towards P aeruginosa in-
fections has been associated with improved clinical outcomes in
people with CF and both inhaled and oral antibiotic therapies
are recommended in that cohort (NICE 2017). There is no clear
guidance on whether treatments targeted towards BCC are effec-
tive, but inhaled antibioticsmay theoretically overcome traditional
resistance breakpoints due the 100-fold increased concentrations
achieved in the lung. Hence antimicrobial agents, with little or
no activity against BCC at systemically achievable concentrations,
may still exert bactericidal effects when inhaled into the lungs
(Ramsey 1999).
Furthermore,macrolides have no in vitro bactericidal effect against
P aeruginosa, yet appear to producemarked clinical improvements.
This is most likely secondary to an anti-inflammatory effect with
attenuated cytokine production and reductions in neutrophil elas-
tase reported in a number of studies (Bell 2005; Wales 1999).
Hence, despite BCC often demonstrating in vitro resistance to
many of the antimicrobial agents available for chronic use in CF,
there is hope that the principles of treatment and agents used in
chronic P aeruginosa infection are relevant in BCC infection.
Why it is important to do this review
Chronic infection with BCC is associated with poorer clinical out-
comes in people with CF. The inherent antibiotic resistance in
these species makes the treatment of chronic infection challeng-
ing for clinicians. This review aims to assess the current evidence
with regards to antibiotic treatment options for people with CF
who are chronically infected with BCC to identify evidence-based
strategies.
Strategies will primarily be assessed in terms of their ability to
preserve or improve pulmonary function and to reduce acute pul-
monary exacerbations.
O B J E C T I V E S
The objective of this review is to assess the effects of long-term oral
and inhaled antibiotic therapy targeted against chronic BCC lung
infections in people with CF. The primary objective is to assess the
efficacy of treatments in terms of improvements in lung function
and reductions in exacerbation rate. Secondary objectives include
quantifying adverse events, mortality and changes in quality of life
associated with treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (including cross-over trials) will be
considered for inclusion in this review.
Types of participants
Adults and children with CF (confirmed by either a positive sweat
test or the identification of two pathogenic CFTRmutations) and
chronic BCC infection (defined as a positive respiratory culture
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growth of BCC within the last six months and BCC growth in
more than 50% of all respiratory cultures in the last 12 months)
(Lee 2003).
Types of interventions
Long-term (defined as a period of eight weeks or more) antibiotics
(all agents, doses and regimens) via either the inhaled or oral route*.
Trials will be included if there is comparison against no treatment,
placebo, another antibiotic agent, another mode of delivery, or
another dose or regimen of the same antibiotic.
*Antibiotics administered via oral and inhaled route will be anal-
ysed and presented separately.
Types of outcome measures
Primary outcomes
1. Lung function
i) Forced expiratory volume in one second (FEV1)
a) Absolute change in volumes, % predicted or both
b) Relative change in volumes, % predicted or both
2. Pulmonary exacerbations
i) Time to next exacerbation
ii) Hospitalisations
iii) Exacerbation rate
iv) IV antibiotic use
3. Adverse events
i) Proportion of participants who had to withdraw or
change therapy
a) mild: transient event, no treatment change, e.g.
rash, nausea, diarrhoea
b) moderate: treatment discontinued, e.g.
nephrotoxicity, ototoxicity, hepatitis, visual impairment
c) severe: causing hospitalisation or death
Secondary outcomes
1. Mortality
2. Quality of life (QoL)
i) Validated QoL score (e.g. CFQ-R, CRISS score)
3. BCC culture
i) Sputum density of BCC
4. Changes in inflammatory markers
i) Sputum or bronchoalveolar lavage (BAL) samples
ii) Serum or blood
Search methods for identification of studies
We will formulate a comprehensive search strategy in an attempt
to identify all relevant trials regardless of language or publication
status (published, unpublished, in press, and in progress).
Electronic searches
The Cochrane Cystic Fibrosis and Genetic Disorders Group’s In-
formationSpecialist will conduct a systematic search of theGroup’s
Cystic Fibrosis Trials Register for relevant trials using the following
terms:cystic fibrosis and (burkholderia OR cepacia).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant section of the Cochrane Cystic
Fibrosis and Genetic Disorders Group’s website.
We will search the following trials registries:
• the World Health Organization (WHO) International
Clinical Trials Registry Platform ( www.who.int/trialsearch)
• Clinicaltrials.gov ( www.clinicaltrials.gov)
See an appendix for details of the searches (Appendix 1).
Searching other resources
We will check the references of included trials and any relevant
systematic reviews identified for further references to relevant tri-
als.
Data collection and analysis
Selection of studies
Two review authors (FF, DN) will independently select trials to
be included in the review. Where there is disagreement on the
suitability of a trial for inclusion, all three review authors will
attempt to reach a consensus decision after discussion.
Data extraction and management
Each author will independently extract data using standardised
data collection forms. If there are any disagreements over the suit-
ability of trials for inclusion in the review, we will aim to reach
a consensus after discussion between all three review authors. We
plan to compare outcomemeasures at eight weeks to threemonths,
over three months to six months and over six months to one year.
However, if we identify trials with outcome data at alternative
time-points, we will also consider these. We will analyse oral and
inhaled antibiotics separately.
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Assessment of risk of bias in included studies
Each review author will independently assess trials following the
domain-based evaluation as described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a). Briefly, a
judgement of ’low risk’, ’high risk’ or ’unclear risk’ of bias will be
made for each of the seven domains in theCochrane tool which.are
listed below.
• Random sequence generation
• Allocation concealment
• Blinding of participant personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective reporting
• Other sources of bias
If there are any disagreements between the three review authors,
then we aim to reach a consensus by discussion.
Measures of treatment effect
For continuous outcomes, such as change in lung function and
time to next exacerbation, we will calculate the mean difference
(MD) with corresponding 95% confidence intervals (CI) to mea-
sure treatment effect. If trials report multiple variations of a sim-
ilar outcome, we will calculate the standardized mean difference
(SMD) and corresponding 95% CIs.
For dichotomous outcomes such as mortality, we will calculate
odds ratios (OR) and corresponding CIs.
Unit of analysis issues
Given the long-term nature of the interventions we are investigat-
ing in this review, it is unlikely that we will identify any eligible
cross-over trials; however, should we identify these, we will include
data from such trials should the duration of treatment meet the
inclusion criteria and if the relevant information, as described by
Elbourne is available (Elbourne 2002). We aim to treat the trials
as parallel trials and pool the intervention arms to be compared
against the control arms, or alternatively perform analysis on the
first period only.We will choose the method of analysis dependent
on the information available.
Dealing with missing data
We will assess for missing data in reported results and report the
percentage of participants from whom no outcome data were ob-
tained on the data collection form. Unless there is reason to sus-
pect data are not missing at random, we will include data on only
those whose results are known in the analysis and use the total
participants with complete data as the denominator rather than
the total number of participants (Higgins 2011b).
Assessment of heterogeneity
We will assess heterogeneity of inconsistencies across trials using
the I² statistic. We will interpret the I² statistic based on the thresh-
olds of heterogeneity set out by Higgins (Higgins 2003):
• 0% to 40%: might not be important;
• 30% to 60%: may represent evidence of moderate
heterogeneity;
• 50% to 90%: may represent evidence of substantial
heterogeneity;
• 75% to 100%:may represent evidence of considerable
heterogeneity.
Assessment of reporting biases
If we are able to include a sufficient number of trials (10 or more as
recommended by the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a)), we will attempt to assess whether
our review is subject to publication bias by using a funnel plot. If
we detect asymmetry, wewill explore causes other than publication
bias.
Data synthesis
We will assess whether trials are clinically similar enough to com-
bine into a meta-analysis, and if so, will assess for heterogeneity
as set out above. If there is substantial heterogeneity (higher than
50%), we will undertake a random-effects meta-analysis, other-
wise, we will use a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
Wewill conduct a subgroup analysis of outcomes in included trials
for B cenocepacia and B multivorans.
Where it is reported, we will record outcome effects adjusted for
the intermittent use of acute antibiotics during the trial period and
wewill conduct a subgroup analysis using these reported outcomes
if there are sufficient data available.
Sensitivity analysis
If there are sufficient trials included (10 ormore) wewill review the
validity of our conclusions in a sensitivity analysis. Firstly, we will
carry out a sensitivity analysis to assess the influence of a high risk
of bias in any domain on our results and conclusions. Secondly, if
a fixed-effect model is used in an analysis, a random-effects model
will also be tested, and vice-versa.
Summary of findings table
We will prepare summary of findings tables for each comparison
included in the review, when, within each comparison, there is at
least one included trial of any antibiotic therapy targeting chronic
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BCC infection. We will include reported changes in the primary
outcomes FEV1 (changes in relative % predicted or volumes or
both), time to next exacerbation and hospitalisations, mortality
and adverse events (mild, moderate and severe). We will list pop-
ulation, setting, intervention and comparison and report an il-
lustrative risk for the experimental and control intervention with
MDs re-expressed as ORs if required (Schünemann 2011b). The
grade of overall quality will be given using the Grading of Recom-
mendations Assessment, Development and Evaluation ( GRADE)
with comments ( Schunemann 2006).
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A P P E N D I C E S
Appendix 1. Search strategies - trial registries
Registry Search terms
WHO ICTRP Search terms: burkholderia OR cepacia
Study type: interventional studies
Condition: cystic fibrosis
Phase: any
ClinicalTrials.gov Condition: cystic fibrosis
Intervention: antibiotic OR antimicrobial
Phase: any
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